ESMO guidelines adapted for NSCLC in patients of Asian ancestry

  • Park K & al.
  • Ann Oncol
  • 1 Feb 2020

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • An adapted European Society for Medical Oncology (ESMO) guideline for the diagnosis, treatment, and follow-up of NSCLC includes specific recommendations for the treatment of patients of Asian ancestry.
  • The adaptation is detailed in a consensus statement from oncology experts representing Korea, China, India, Japan, Malaysia, Singapore, and Taiwan.

Why this matters

  • The adapted guidelines include changes reflecting differences related to ethnicity, cancer biology, and standard practices in participating Asian countries.

Key changes

  • The panel added a new recommendation for the consolidation administration of durvalumab 1-42 days after the end of chemoradiotherapy (10 mg/kg every 2 weeks for up to 12 months).
  • In patients with negative biopsy results following endobronchial and/or endoscopic ultrasound, alternative methods to mediastinoscopy may be used if it is unavailable.
  • A multidisciplinary assessment, especially for determination of resectability, is recommended.
  • Carboplatin monotherapy may be considered in combination with radiation for patients >70 years with stage III disease.
  • The management of radiation toxicities may require more frequent follow-up during the first year.